GlassScriptPhysician profile
Caroline C Day
NPI 1184075301
$4,878.45
in general payments reported to CMS, 2019-2025
25 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $706 · 2023: $768 · 2024: $1,612 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,412.38 |
| Education | $316.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.51 | 2021-2025 | |
| Genzyme Corporation | $590.43 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $423.55 | 2021-2024 | Ilumya, Blu-U |
| Novartis Pharmaceuticals Corporation | $420.11 | 2021-2025 | |
| Lilly USA, LLC | $342.31 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $317.39 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $295.75 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $223.47 | 2022-2025 | Dupixent |
| Amgen INC. | $180.55 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $131.63 | 2022-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $128.81 | 2022-2024 | Adbry |
| Incyte Corporation | $124.54 | 2023-2025 | Opzelura |
| Pfizer INC. | $111.71 | 2021-2025 | |
| Ucb, INC. | $103.49 | 2023-2024 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $83.10 | 2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $57.96 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $56.94 | 2021 | |
| Organogenesis INC. | $48.40 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.98 | 2024 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.96 | 2022-2024 | Spevigo |
| Almirall LLC | $26.60 | 2022 | |
| Dermavant Sciences, INC. | $20.45 | 2024 | Vtama |
| Lnhc, INC | $18.83 | 2025 | Zelsuvmi |
| Sandoz INC. | $15.98 | 2024 | Hyrimoz |
| Organon LLC | $4.00 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.